{
  "success": true,
  "pagesUsed": [
    2,
    3,
    9,
    15,
    16
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL SUMMARY",
        "text": "PROTOCOL SUMMARY",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "PROTOCOL SUMMARY",
        "sectionType": {
          "id": "13741651-d5ca-42d9-a79f-28a1651d6dd6",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_1_1",
          "nci_1_2",
          "nci_1_3"
        ]
      },
      {
        "id": "nc_2",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "582275cb-fb95-4cd6-b84e-a08baf4daedb",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3"
        ]
      },
      {
        "id": "nc_3",
        "name": "OBJECTIVES AND ENDPOINTS",
        "text": "OBJECTIVES AND ENDPOINTS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "OBJECTIVES AND ENDPOINTS",
        "sectionType": {
          "id": "678749af-d11b-4cd1-87bc-a224fb217d6b",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1"
        ]
      },
      {
        "id": "nc_4",
        "name": "STUDY DESIGN",
        "text": "STUDY DESIGN",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "STUDY DESIGN",
        "sectionType": {
          "id": "0efb127c-cfa7-4fcf-a967-12ef0bfdd6e2",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4"
        ]
      },
      {
        "id": "nc_5",
        "name": "STUDY POPULATION",
        "text": "STUDY POPULATION",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "STUDY POPULATION",
        "sectionType": {
          "id": "f3a1cc8b-4897-4457-a57c-7901ec7779b0",
          "code": "Study Population",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Population",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3"
        ]
      },
      {
        "id": "nc_6",
        "name": "Appendix 6: Liver and other safety: actions and follow-up assessments",
        "text": "Appendix 6: Liver and other safety: actions and follow-up assessments",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10.6",
        "sectionTitle": "Appendix 6: Liver and other safety: actions and follow-up assessments",
        "sectionType": {
          "id": "ab643428-c851-4606-aab4-8b1cccad20bf",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "Appendix 8A: Examples of drugs with a potential to change SAR442168 metabolism",
        "text": "Appendix 8A: Examples of drugs with a potential to change SAR442168 metabolism",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10.8",
        "sectionTitle": "Appendix 8A: Examples of drugs with a potential to change SAR442168 metabolism",
        "sectionType": {
          "id": "b169378f-029d-4af1-b6b2-e8ba0e993fcd",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_8",
        "name": "Country-specific provisions for the US, Brazil, Israel, and sites following FDA partial clinical hold conditions",
        "text": "Country-specific provisions for the US, Brazil, Israel, and sites following FDA partial clinical hold conditions",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10.11.4",
        "sectionTitle": "Country-specific provisions for the US, Brazil, Israel, and sites following FDA partial clinical hold conditions",
        "sectionType": {
          "id": "1baccfef-1c1e-4452-988b-f70b03922fcf",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "Appendix 12: Protocol amendment history",
        "text": "Appendix 12: Protocol amendment history",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10.14",
        "sectionTitle": "Appendix 12: Protocol amendment history",
        "sectionType": {
          "id": "2c22cda0-2d5e-4279-ad38-4b78048e44cb",
          "code": "Appendix",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Appendix",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_1_1",
        "name": "SYNOPSIS",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "SYNOPSIS"
      },
      {
        "id": "nci_1_2",
        "name": "SCHEMA",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "SCHEMA"
      },
      {
        "id": "nci_1_3",
        "name": "SCHEDULE OF ACTIVITIES (SOA)",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "SCHEDULE OF ACTIVITIES (SOA)"
      },
      {
        "id": "nci_2_1",
        "name": "STUDY RATIONALE",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "STUDY RATIONALE"
      },
      {
        "id": "nci_2_2",
        "name": "BACKGROUND",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "BACKGROUND"
      },
      {
        "id": "nci_2_3",
        "name": "BENEFIT/RISK ASSESSMENT",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3",
        "sectionTitle": "BENEFIT/RISK ASSESSMENT"
      },
      {
        "id": "nci_3_1",
        "name": "APPROPRIATENESS OF MEASUREMENTS",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "APPROPRIATENESS OF MEASUREMENTS"
      },
      {
        "id": "nci_4_1",
        "name": "OVERALL DESIGN",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "OVERALL DESIGN"
      },
      {
        "id": "nci_4_2",
        "name": "SCIENTIFIC RATIONALE FOR STUDY DESIGN",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "SCIENTIFIC RATIONALE FOR STUDY DESIGN"
      },
      {
        "id": "nci_4_3",
        "name": "JUSTIFICATION FOR DOSE",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "JUSTIFICATION FOR DOSE"
      },
      {
        "id": "nci_4_4",
        "name": "END OF STUDY DEFINITION",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.4",
        "sectionTitle": "END OF STUDY DEFINITION"
      },
      {
        "id": "nci_5_1",
        "name": "INCLUSION CRITERIA",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.1",
        "sectionTitle": "INCLUSION CRITERIA"
      },
      {
        "id": "nci_5_2",
        "name": "EXCLUSION CRITERIA",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2",
        "sectionTitle": "EXCLUSION CRITERIA"
      },
      {
        "id": "nci_5_3",
        "name": "LIFESTYLE CONSIDERATIONS",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3",
        "sectionTitle": "LIFESTYLE CONSIDERATIONS"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "SoA",
        "expandedText": "Schedule of activities",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "CYP3A",
        "expandedText": "Cytochrome P450 3A",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "CYP2C8",
        "expandedText": "Cytochrome P450 2C8",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "DDI",
        "expandedText": "Drug-drug interaction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "FDA",
        "expandedText": "Food and Drug Administration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "DMTs",
        "expandedText": "disease-modifying therapies",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "RMS",
        "expandedText": "relapsing multiple sclerosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CNS",
        "expandedText": "central nervous system",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "MS",
        "expandedText": "multiple sclerosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "MRI",
        "expandedText": "magnetic resonance imaging",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "BTK",
        "expandedText": "Bruton’s tyrosine kinase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "Gd-",
        "expandedText": "gadolinium-",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "EOS",
        "expandedText": "end of study",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "R",
        "expandedText": "randomization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "D-28",
        "expandedText": "Day-28",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "D-1",
        "expandedText": "Day-1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "D1",
        "expandedText": "Day 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "IMP",
        "expandedText": "Investigational Medicinal Product",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "LTS",
        "expandedText": "Long-term Safety Study",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "pEOT",
        "expandedText": "premature End of Treatment",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "FUV",
        "expandedText": "Follow-up visit",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 9,
      "itemCount": 14,
      "abbreviationCount": 21
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2)",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "1",
      "versionDate": "20-Dec-2023",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "SoA",
          "expansion": "Schedule of activities"
        },
        {
          "abbreviation": "CYP3A",
          "expansion": "Cytochrome P450 3A"
        },
        {
          "abbreviation": "CYP2C8",
          "expansion": "Cytochrome P450 2C8"
        },
        {
          "abbreviation": "DDI",
          "expansion": "Drug-drug interaction"
        },
        {
          "abbreviation": "FDA",
          "expansion": "Food and Drug Administration"
        },
        {
          "abbreviation": "DMTs",
          "expansion": "disease-modifying therapies"
        },
        {
          "abbreviation": "RMS",
          "expansion": "relapsing multiple sclerosis"
        },
        {
          "abbreviation": "CNS",
          "expansion": "central nervous system"
        },
        {
          "abbreviation": "MS",
          "expansion": "multiple sclerosis"
        },
        {
          "abbreviation": "MRI",
          "expansion": "magnetic resonance imaging"
        },
        {
          "abbreviation": "BTK",
          "expansion": "Bruton’s tyrosine kinase"
        },
        {
          "abbreviation": "Gd-",
          "expansion": "gadolinium-"
        },
        {
          "abbreviation": "EOS",
          "expansion": "end of study"
        },
        {
          "abbreviation": "R",
          "expansion": "randomization"
        },
        {
          "abbreviation": "D-28",
          "expansion": "Day-28"
        },
        {
          "abbreviation": "D-1",
          "expansion": "Day-1"
        },
        {
          "abbreviation": "D1",
          "expansion": "Day 1"
        },
        {
          "abbreviation": "IMP",
          "expansion": "Investigational Medicinal Product"
        },
        {
          "abbreviation": "LTS",
          "expansion": "Long-term Safety Study"
        },
        {
          "abbreviation": "pEOT",
          "expansion": "premature End of Treatment"
        },
        {
          "abbreviation": "FUV",
          "expansion": "Follow-up visit"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis (GEMINI 2)",
        "version": "1",
        "versionDate": "20-Dec-2023"
      },
      "sections": [
        {
          "number": "1",
          "title": "PROTOCOL SUMMARY",
          "type": "Synopsis",
          "subsections": [
            {
              "number": "1.1",
              "title": "SYNOPSIS"
            },
            {
              "number": "1.2",
              "title": "SCHEMA"
            },
            {
              "number": "1.3",
              "title": "SCHEDULE OF ACTIVITIES (SOA)"
            }
          ]
        },
        {
          "number": "2",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "2.1",
              "title": "STUDY RATIONALE"
            },
            {
              "number": "2.2",
              "title": "BACKGROUND"
            },
            {
              "number": "2.3",
              "title": "BENEFIT/RISK ASSESSMENT"
            }
          ]
        },
        {
          "number": "3",
          "title": "OBJECTIVES AND ENDPOINTS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "3.1",
              "title": "APPROPRIATENESS OF MEASUREMENTS"
            }
          ]
        },
        {
          "number": "4",
          "title": "STUDY DESIGN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "4.1",
              "title": "OVERALL DESIGN"
            },
            {
              "number": "4.2",
              "title": "SCIENTIFIC RATIONALE FOR STUDY DESIGN"
            },
            {
              "number": "4.3",
              "title": "JUSTIFICATION FOR DOSE"
            },
            {
              "number": "4.4",
              "title": "END OF STUDY DEFINITION"
            }
          ]
        },
        {
          "number": "5",
          "title": "STUDY POPULATION",
          "type": "Study Population",
          "subsections": [
            {
              "number": "5.1",
              "title": "INCLUSION CRITERIA"
            },
            {
              "number": "5.2",
              "title": "EXCLUSION CRITERIA"
            },
            {
              "number": "5.3",
              "title": "LIFESTYLE CONSIDERATIONS",
              "subsections": [
                {
                  "number": "5.3.1",
                  "title": "Meals and dietary restrictions"
                },
                {
                  "number": "5.3.2",
                  "title": "Caffeine, alcohol, and tobacco"
                },
                {
                  "number": "5.3.3",
                  "title": "Activity"
                }
              ]
            }
          ]
        },
        {
          "number": "10.6",
          "title": "Appendix 6: Liver and other safety: actions and follow-up assessments",
          "type": "Appendix"
        },
        {
          "number": "10.8",
          "title": "Appendix 8A: Examples of drugs with a potential to change SAR442168 metabolism",
          "type": "Appendix"
        },
        {
          "number": "10.11.4",
          "title": "Country-specific provisions for the US, Brazil, Israel, and sites following FDA partial clinical hold conditions",
          "type": "Other"
        },
        {
          "number": "10.14",
          "title": "Appendix 12: Protocol amendment history",
          "type": "Appendix"
        }
      ]
    }
  }
}